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Abstract
Direct oral anticoagulants are at least as effective as 
vitamin K antagonists for the prevention and treatment 
of thromboembolism. Unfortunately, differently from 
vitamin K antagonists, they have the great drawback 
of lacking specific antidotes in the case of bleeding or 
emergency situations such as trauma, stroke requiring 
thrombolysis, and urgent surgery. The progressive 
development of antidotes for these new drugs, which, it 
is hoped, will become available in the near future, will 
allow better and safer management of the rapid reversal 
of their anticoagulant effect.
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Introduction
Anticoagulant therapy is a fundamental approach for 
the prevention and treatment of thromboembolic diseases 
and the currently available therapeutic armamentarium 
includes unfractionated heparin, low-molecular-weight 
heparins and vitamin K antagonists (VKA)1-3. Moreover, 
a new class of direct oral anticoagulants (DOAC) 
has been developed in the last decade to overcome 
the main limitations of traditional anticoagulants, i.e. 
parenteral administration and onset of thrombocytopenia 
for heparins, and the need for routine International 
Normalised Ratio (INR) monitoring and susceptibility 
to a number of food and drug interactions for VKA4-6. 
Two types of DOAC are currently available: the factor 
Xa inhibitors apixaban, edoxaban, and rivaroxaban and 
the thrombin inhibitor dabigatran (see Figure 1 and 
Table I for the description of their mechanisms of action 
and main characteristics, respectively)7. Unlike VKA, 
which block the formation of multiple, active vitamin 
K-dependent coagulation factors, DOAC antagonise 
the activity of a single step in coagulation7. In addition 
to their above mentioned practical advantages, at the 
moment there is robust evidence from several phase 3 
trials that DOAC are at least as effective as VKA for 
the prevention and treatment of thromboembolism8-23. 
However, as the most feared complication of VKA is the 
onset of severe haemorrhage, especially intracerebral24, 
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Figure 1 - Mechanisms of action of direct oral anticoagulants. 
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the comparison between these two classes of drugs is 
based mainly on the ability of DOAC to reduce the 
incidence of life-threatening bleeding complications25-28. 
In this review, after a brief discussion of the safety 
of DOAC, we summarise the current knowledge on 
the management of bleeding complications associated 
with the use of DOAC. A section is also dedicated to 
the current status of development of specific antidotes. 
Finally we propose a treatment algorithm based on the 
literature and our personal experience.
Safety of direct oral anticoagulants 
The results of large, randomised licensing trials have 
shown that bleeding rates with DOAC are generally the 
same or even lower than the bleeding rates with VKA 
and a number of meta-analyses pooling together the data 
from such trials have confirmed these findings29-36. Thanks 
to their efficacy and safety profile37, DOAC are being 
increasingly used in clinical practice worldwide38-40. In 
parallel, to validate the data from phase 3 trials, a number 
of real-world studies have recently been completed and 
their results have been published. A nationwide Danish 
prospective cohort study, assessing the safety and efficacy 
of dabigatran vs warfarin for the treatment of patients with 
atrial fibrillation in everyday clinical practice, found that 
the rates of major bleeding and gastrointestinal bleeding 
were similar between the dabigatran and warfarin groups: 
for major bleeding the adjusted hazard ratio (aHR) with 
95% confidence interval (95% CI) was 0.82 (0.59-1.12) 
in the dabigatran 110 mg group, and 0.77 (95% CI: 
0.51-1.13) in the dabigatran 150 mg group, while for 
gastrointestinal bleeding the aHR was 0.60 (95% CI: 
0.37-0.93) in the dabigatran 110 mg group, and 1.12 
(95% CI: 0.67-1.83) in the dabigatran 150 mg group41. 
However, a study carried out in the USA in a large 
population of elderly Medicare patients, comparing 
the safety of dabigatran (75 or 150 mg twice daily) vs 
warfarin, showed that dabigatran was associated with 
a significantly reduced risk of ischaemic stroke (aHR: 
0.80; 95% CI: 0.67-0.96), intracranial haemorrhage 
(aHR: 0.34; 95% CI: 0.26-0.46) and death (aHR: 0.86; 
95% CI: 0.77-0.96), but with an increased risk of major 
gastrointestinal bleeding (aHR: 1.28; 95% CI: 1.14-1.44)42. 
A similar gastrointestinal bleeding risk between the 
DOAC dabigatran and rivaroxaban and warfarin was 
observed in two studies conducted in the USA on large 
populations of commercially insured adults43,44, although 
particular caution was recommended when prescribing 
such novel oral anticoagulants to older people (>75 
years) due to an increased gastrointestinal bleeding 
risk44. In the Dresden prospective registry, the observed 
6.1% of rivaroxaban-related major bleeding was lower 
and the outcome (6.3% of bleeding-related case fatality 
rates at day 90) better than that reported for VKA45. An 
update from the same registry showed that only a small 
proportion (5.3%) of reported bleeding events observed 
with DOAC were major46. Overall, these post-marketing, 
real-life efficacy data document that a number of DOAC-
associated bleeding events do occur. The management of 
such events can be a major concern among physicians 
because of the lack of specific antidotes (see below). 
Recently, various reviews and the opinions of panels 
of experts on the treatment of DOAC-related bleeding 
have been published with the aim of filling the gap 
consequent to the lack of evidence based on clinical 
trials26,27,47-49. 
Management of bleeding associated with direct 
oral anticoagulants 
Since their introduction, one of the potential 
downsides of  DOAC administration has been the absence 
of specific antidotes to reverse their anticoagulant 
effects. Until an antidote becomes available for clinical 
use, supportive care remains the pillar of the treatment 
of haemorrhagic complications; however, based on 
experience with VKA-related bleeding24,50-53, the use of 
Table I - Characteristics of the new oral anticoagulants.
Characteristics Direct thrombin inhibitor Factor Xa inhibitors
Dabigatran Apixaban Edoxaban Rivaroxaban
Prodrug Yes No No No
Bioavailability (%) 3-7 50 62 80
Time to peak concentration (hours) 1-3 1-3 1-3 2-4
Half-life (hours) 12-17 8-15 8-10 7-13
Renal clearance (%) 80 25 35 36
Elimination Urine and faeces Urine and faeces Urine and faeces Urine and faeces
Dosing regimen 110-150 mg twice daily 2.5-5 mg twice daily 15-30 mg once daily 10-30 mg once daily
Metabolism P-glycoprotein P-glycoprotein, 
CYP3A4
P-glycoprotein, 
CYP3A4
P-glycoprotein, 
CYP3A4
Antidotes under development Idarucizumab, 
modified thrombin molecules
Andexanet alfa, 
Aripazine
Andexanet alfa, 
Aripazine
Andexanet alfa, 
Aripazine
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fresh-frozen plasma, prothrombin complex concentrates 
(PCC), or recombinant activated factor VIIa (rFVIIa) 
has been proposed54,55. In addition, although it is not 
usually necessary to monitor the anticoagulant effects of 
DOAC, an assessment of coagulation status is necessary 
in the case of major bleeding, trauma, urgent surgery 
or overdose (for the most appropriate tests for the 
quantitative measurement of the anticoagulant activity 
of DOAC, see reference 28).
In most cases of DOAC-associated mild bleeding, 
considering their short half-life, drug discontinuation, 
investigation of the source of bleeding, and general 
supportive measures can be adopted. The general 
management of major bleeding includes prompt control 
of the haemorrhage by mechanical compression, surgical 
or endoscopic haemostasis, radiological interventional 
procedures, transfusion of blood components and 
haemodynamic support with fluid replacement as 
well as the use of adjunctive haemostatic agents (i.e., 
antifibrinolytics or desmopressin)28. 
Other possible therapies exploited include 
haemodialysis and activated charcoal. Haemodialysis 
may reverse the anticoagulant effects of dabigatran 
overdose because of the low protein binding (35%) 
of this drug56 and, in a single-centre study in patients 
with end-stage renal disease, it proved to be effective 
in removing approximately 70% of a single 50-mg dose 
of dabigatran at 4 hours57. However, it is not effective 
for rivaroxaban or apixaban because these drugs are 
highly protein bound (95% and 87%, respectively)58,59. 
Oral activated charcoal can be used if a recent (<2-3 
hours) overdose of dabigatran is suspected, as shown 
by in vitro data60, but no data are available on factor 
Xa inhibitors. 
This review focuses on the use of non-specific 
procoagulant agents and specific antidotes (though 
currently still at various stages of clinical development) 
that can be used for the urgent reversal of anticoagulation 
with DOAC in severe acute haemorrhage61. Figure 2 
presents a proposed treatment algorithm for patients 
with DOAC-associated bleeding patients or at high risk 
of bleeding.
Non-specific procoagulant agents
In the case of serious bleeding, in the absence of 
specific antidotes, non-specific procoagulant agents 
(PCC, activated prothrombin complex concentrates 
[aPCC)], and rFVIIa) have been used for their 
capacity to reverse the anticoagulant effects of 
DOAC. 
Minor bleeding STOP DOAC 
 Haemostatic therapies (first-line option: PCC,  aPCC; 
second-line option: rFVIIa); 
 Oral charcoal for dabigatran ingestion (<2-3 hours); 
 Haemodialysis for dabigatran removal. 
Major bleeding 
DOAC-associated bleeding  
STOP bleeding 
 Local measures; 
 Discontinue 1 or 2 doses  
       (if necessary). 
YES 
NO 
 Discontinue drug;  
 Local measures; 
 Laboratory monitoring (blood cell count, 
CrCL, liver function, coagulation tests for 
DOACs, if available); 
 Haemodynamic/Transfusion support; 
 Adjunctive therapies (antifibrinolytics, 
DDAVP). 
Figure 2 - Treatment algorithm for patients with direct oral anticoagulant-associated bleeding or at high 
risk of bleeding. 
 DOAC: direct oral anticoagulant; CrCl: creatinine clearance; DDAVP: desmopressin; PCC: prothrombin 
complex concentrate; aPCC: activated prothrombin complex concentrate; rFVIIa: recombinant activated 
factor VII; hs: hours.
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PCC contain various amounts of vitamin K-dependent 
coagulation factors (factors II, IX and X and proteins 
C and S) and are classified as three-factor PCC or as 
four-factor PCC, if they contain factor VII62.
Pre-clinical studies on the efficacy of PCC in the 
reversal of the anticoagulant effect of DOAC have 
yielded conflicting results63. On the one hand, a mice 
model of intracerebral haemorrhage64 and a rabbit 
model of kidney injury65 showed good effects of PCC 
in limiting haematoma growth and blood loss associated 
with dabigatran while another study demonstrated 
that four-factor PCC was able to reduce rat (tail vein) 
bleeding time significantly66. 
On the other hand, successive studies pointed out 
that PCC had no effect on dabigatran-related bleeding 
in mice67 or on the reversal of the effects of rivaroxaban 
in a rabbit model of hepatosplenic bleeding, despite 
partial correction of laboratory parameters68. 
Moreover, in separate studies, the addition of PCC 
to rivaroxaban-spiked plasma in vitro did not change 
abnormal coagulation tests, thromboelastometry or 
thrombin generation tests69,70. An ex vivo randomised, 
double-blind, placebo-controlled study, aimed at 
reversing the effects of dabigatran and rivaroxaban 
in healthy male volunteers, showed that four-factor 
PCC (50 IU/kg) failed to reverse the prolongation 
of the activated partial thromboplastin time, ecarin 
clotting time, or thrombin time in participants treated 
with dabigatran but corrected the prothrombin time 
prolongation and abnormal endogenous thrombin 
potential in those treated with rivaroxaban71. Four-factor 
PCC also improved the thrombin peak and velocity 
indices in thrombin generation of blood from healthy 
male volunteers pre-treated with apixaban72.
The result of an open-label, single-centre, parallel-
group study showed that both four-factor PCC and three-
factor PCC can at least partially reverse the anticoagulant 
effects of rivaroxaban. Administration of either four-
factor or three-factor PCC to 35 healthy volunteers in 
the presence of rivaroxaban appeared to be safe and well 
tolerated, with no signs of thromboembolic events73. 
The three-factor PCC was also able to reverse 
edoxaban-induced thrombin generation inhibition 
in a phase 1, single-dose, placebo-controlled trial74. 
However, we must underline that all human studies 
carried out so far in this clinical setting have exploited 
healthy volunteers without active bleeding. Therefore, 
we still do not know whether and how the corrections of 
the laboratory tests modified by DOAC translate into a 
clinical benefit. Furthermore, at the moment, we do not 
have robust data to recommend four-factor PCC over 
three-factor PCC or vice versa in this setting, although 
data supporting the use of four-factor PCC are probably 
more consistent71,72.
Finally, from the analysis of the available literature 
data, PCC (50 IU/kg) seems to be more effective for 
bleeding associated with oral anti-FXa inhibitors than for 
that associated with oral direct thrombin inhibitors. PCC 
should be preferred over fresh-frozen plasma for DOAC 
reversal as they provide a more rapid and sustained 
replacement of multiple factors in a small volume and 
also theoretically carry a lower risk of transmitting 
infections because of the viral inactivation process62.
aPCC (factor VIII inhibitor bypassing activity, FEIBA) 
contain factors II, VII, IX and X, which are activated during 
the industrial production process. Several animal and in 
vitro studies on the reversal of the anticoagulant effects 
of dabigatran, rivaroxaban and apixaban demonstrated 
that aPCC are able to correct some abnormal clot-based 
coagulation tests, thromboelastometry parameters and 
thrombin generation indices75-78. In fact, while PCC, aPCC 
and rFVIIa corrected the prolongation of the prothrombin 
time and reduced bleeding time in rivaroxaban-treated 
rats, only aPCC reduced bleeding time in primates 
treated with rivaroxaban77. In an ex vivo study of healthy 
male volunteers, carried out by Marlu and colleagues79, 
both four-factor PCC and FEIBA were able to reverse 
the anticoagulant effect of dabigatran and rivaroxaban 
but aPCC were more efficacious. Another ex vivo 
experimental study showed that FEIBA, at a dose of 50 
IU/kg, corrected thrombin generation in the plasma of 
patients treated with dabigatran80. Another study showed 
that PCC, aPCC and rFVIIa all corrected the prolongation 
of prothrombin time when added to plasma from patients 
receiving rivaroxaban, but only PCC and aPCC modified 
all abnormal thrombin generation indices81. A recent 
study by Martin and collaborators showed that aPCC 
was more effective than PCC or rFVIIa in reversing, in 
vitro, the effects of apixaban. aPCC rapidly triggered the 
development of an apparently normal fibrin network and 
corrected latency and quantitative parameters, whereas 
PCC or rFVIIa had only a partial effect82.
Therefore, aPCC (50 IU/kg, maximum 200 IU/kg/day) 
seems promising in reversing the effects of DOAC, 
especially for dabigatran. However, as data from 
well-designed clinical studies are lacking, the aPCC-
associated increased thromboembolic risk should be 
evaluated carefully.
rFVIIa has also been used to reverse the effect 
of DOAC. Although it was not able to stop bleeding 
following treatment with dabigatran or rivaroxaban in 
animal models, in vitro studies suggest a variable effect 
on rivaroxaban- and apixaban-induced haemostatic 
abnormalities64,68,72,83. Similarly to PCC, rFVIIa also 
failed to reverse bleeding induced by rivaroxaban 
overdose68, while both aPCC and rFVIIa significantly 
shortened the bleeding time in edoxaban-treated rats84. 
In an in vitro study, rFVIIa corrected prothrombin time 
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prolongation at a low concentration of rivaroxaban 
(80 ng/µL) and thromboelastometry results at a high 
concentration of rivaroxaban (200 ng/µL)70. In another 
in vitro study analysing the efficacy of PCC, aPCC and 
rFVIIa in reversing the anti-haemostatic activity of 
apixaban, rFVIIa was the most effective in correcting 
clotting time prolongations72. In ex vivo-treated plasma 
samples from healthy volunteers rFVIIa was unable to 
reverse the anticoagulant effect of dabigatran79. Although 
clinical data are lacking, results from pre-clinical studies 
seem to indicate that rFVIIa is less effective than other 
haemostatic agents (i.e., activated or non-activated 
PCC) for the treatment of DOAC-associated bleeding, 
especially when dealing with oral direct thrombin 
inhibitors85. Furthermore, like aPCC, rFVIIa enhances 
the risk of thrombosis. Therefore, rFVIIa (90 µg/kg) 
should be considered as a second-line therapeutic option 
for the treatment of DOAC-associated bleeding, to be 
used after the failure of PCC or aPCC (Figure 2).
Specific antidotes
Several specific antidotes for DOAC are currently 
under development and seem to be promising in early 
clinical trials evaluating their efficacy and safety55.
Idarucizumab, a humanised monoclonal antibody 
fragment (aDabi-Fab), has been produced by Boehringer 
Ingelheim GmbH (Ingelheim am Rhein, Germany) to 
reverse the anticoagulant effect of dabigatran and is 
currently in phase 3 clinical development86,87. It has 
a binding affinity that is about 350 times higher than 
the binding affinity of dabigatran for thrombin but no 
procoagulant or anticoagulant effects and a short half-
life. A randomised, placebo-controlled, double-blind, 
proof-of-concept phase 1 study involving 47 healthy 
male volunteers documented the rapid, complete 
and sustained reversal of the effects of dabigatran 
following administration of idarucizumab, with no 
adverse events88. A phase 3 study (RE-VERSE AD; 
NCT02104947) is currently recruiting patients in more 
than 35 countries worldwide and aims at assessing 
the effect of idarucizumab, at a dose of 5 g, on the 
anticoagulant action of dabigatran in patients treated 
with dabigatran etexilate who have either uncontrolled 
bleeding needing urgent medical intervention (group A) 
or need emergency surgery or procedures necessitating 
rapid reversal of the anticoagulant effect of dabigatran 
(group B). An interim analysis including 90 patients who 
received idarucizumab (51 patients in group A and 39 
in group B) showed that the antibody fragment rapidly 
and completely reversed the anticoagulant activity 
of dabigatran in 88 to 98% of patients89. Similarly 
to previous studies involving more than 200 healthy 
volunteers who were treated with aDabi-Fab88,90,91, no 
safety concerns were reported. A possible theoretical 
challenge is linked to the presence of natural antibodies 
binding to the cleavage site of Fab fragments in about 
15% of normal subjects92. They would not be able to 
block the drug effect but the complexes of dabigatran, 
idarucizumab, and the anti-Fab antibody would no 
longer be filtered by the kidney, because of their 
dimension, thus prolonging the resistance to new doses 
of dabigatran. This problem could be solved simply 
by changing the anticoagulant, in the case that further 
anticoagulation is necessary. Another possible very low 
risk is the formation of anti-idiotype antibodies against 
this antidote, which may sterically mimic dabigatran 
and could become an endogenous thrombin inhibitor.
Modified thrombin molecules such as an active site-
mutated S195A thrombin (S195A-IIa) and its trypsinised 
derivative (γT-S195A-IIa) can also play a role in the 
reversal of dabigatran's effects but clinical data are still 
lacking93. 
As far as antidote development for the direct FXa 
inhibitors is concerned, Portola Pharmaceuticals Inc., 
(San Francisco, CA, USA) has recently produced a 
modified, recombinant activated FX (andexanet alpha, 
PRT064445, AnnexaTM-A), which is catalytically 
inactive but retains high-affinity binding to factor Xa 
inhibitors94. In a phase  1 study on 32 healthy volunteers 
randomised to receive single escalating intravenous 
bolus doses of andexanet alfa or placebo, the anti-FXa 
activity of rivaroxaban, which was added ex vivo, was 
reversed in a dose-dependent manner with no adverse 
events95. Preliminary results of a phase 2, double-blind, 
placebo-controlled trial showed that a bolus dose of 
andexanet alfa antagonised the anti-FXa activity of 
apixaban and rivaroxaban in healthy volunteers96,97. In 
the randomised, double-blind, placebo-controlled phase 
3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the 
Anticoagulant Effects of FXa Inhibitors - Apixaban) 
study, evaluating the safety and efficacy of this antidote 
in older healthy volunteers (50-75 years), andexanet 
alfa produced rapid, sustained and nearly complete 
reversal of the anticoagulant effect of apixaban with 
no serious adverse effects98,99. Finally, in January 2015, 
a phase 3 prospective open-label study to evaluate the 
effect of andexanet in patients receiving FXa-inhibitors 
who have acute major bleeding started100. However, 
as according to the currently available data different 
doses of andexanet alpha seem to be required for the 
two direct FXa inhibitors apixaban and rivaroxaban96, 
it may be challenging to use the appropriate dosage in 
an emergency clinical condition. An additional possible 
concern, as with all structurally modified proteins, is 
immunogenicity of this antidote92.
Another reversal agent is aripazine, or PER977, 
a small, synthetic, water-soluble, cationic molecule 
developed by Perosphere Inc. (Danbury, CT, USA), 
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which binds non-covalently to anticoagulants, inhibiting 
the anticoagulant effects of low molecular weight 
heparins, fondaparinux, the direct oral FXa inhibitors 
and dabigatran through hydrogen bonding and charge-
charge interactions101. Unfortunately, at the moment, 
only limited information about this potential antidote is 
available. In a human plasma ex vivo model, PER977 
reversed the anticoagulant effect of rivaroxaban, 
apixaban, and enoxaparin, measured according to anti-
FXa activity, in a dose-dependent manner across a range 
of concentrations101. A phase 1 study evaluating the safety, 
tolerability, pharmacokinetics and pharmacodynamic 
characteristics of PER977 administered alone or 
following a single dose of edoxaban has recently been 
completed102, while a phase 2 trial evaluating the safety, 
tolerability and effect on coagulation tests of escalating 
doses of PER977 in subjects receiving edoxaban is 
currently underway103. According to the first in vivo 
human data, "baseline hemostasis was restored from 
the anticoagulated state within 10 to 30 minutes after 
administration of 100 to 300 mg of PER977 and was 
sustained for 24 hours"104. Additional phase 2 clinical 
studies are ongoing. Currently, according to Greinacher 
et al.92, the main challenges for this antidote are its 
unclear mode of action and monitoring of reversal 
therapy, because it may reverse bleeding without 
reversing the altered clotting assays.
Conclusions
DOAC are at least as effective as VKA for the 
prevention and treatment of thromboembolism. In addition, 
post-marketing data show that the safety of DOAC in the 
real world is similar to that observed in the published, large 
clinical trials, although particular caution is needed when 
dealing with elderly patients, who have a higher risk of 
bleeding, particularly from the gastrointestinal tract. Thanks 
to their proven efficacy and predictable anticoagulant 
effect, without need for routine monitoring, the DOAC are 
gradually replacing VKA for several indications. However, 
unlike VKA, which can be reversed by PCC, they have 
the important disadvantage of lacking specific antidotes 
in the case of emergency situations such as trauma, stroke 
requiring thrombolysis, and urgent surgery. The progressive 
development of antidotes for these new drugs which, it is 
hoped, will become available in the near future will allow 
better, quicker, and safer management of the reversal of 
the drugs' effects. Meanwhile, shared treatment policies 
and algorithms can play a key role in the case emergency 
reversal is needed. 
The Authors declare no conflict of interest.
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